Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Typically administered as an injection. [10] Victoza: One of Novo Nordisk’s name-brand versions of injectable liraglutide.

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Bengaluru-based Biocon – which is known for its expertise in developing complex biosimilars – has become the first company to ...

A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, ...

BEN Shephard awkwardly stepped in on today’s This Morning when former politician Nadine Dorries repeatedly plugged a pharmaceutical business on air. The TV star intervened when former ...